Other News To Note

 APP Pharmaceuticals Inc., of Schaumburg, ILL., and The Medicines Co. (MDCO), of Parsippany, N.J., settled litigation related to APP's abbreviated new drug application for a generic version of the anti-clotting drug Angiomax (bivalirudin for injection). MDCO licensed APP to begin selling APP's generic version of Angiomax in the U.S. on May 1, 2019, or earlier, in certain circumstances.